Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Breasi-CRISPR Ccnd2 Thr280Ala mutation E13.5-E15.5 embryonic mouse cortex with CRISPR silent controls

ABSTRACT: The increasing availability and affordability of genetic testing has resulted in the identification of numerous novel variants associated with neurodevelopmental disorders. There remains a need for methods to analyze the functional impact of these variants. Some methods, like expressing these variants in cell culture, may be rapid, but lack physiologic context. Other methods, like making a whole mouse model may provide physiologic accuracy, but are costly and time consuming. We recently developed a technique, Breasi-CRISPR, which results in efficient genome editing of neural precursor cells via electroporation of CRISPR-CAS9 reagents into developing mouse brains. Since Breasi-CRISPR is extremely rapid, and enables the analysis of targeted genes in vivo, we wondered if this technique would accelerate the study of monogenic neurodevelopmental disorders. Here, we use Breasi-CRISPR to model megalencephaly postaxial polydactyly polymicrogyria hydrocephalus (MPPH) syndrome. We found that two days after Breasi-CRISPR, we were able to see neurodevelopmental phenotypes known to be associated with MPPH syndrome including increased cyclin D2 protein abundance and an increase in neural progenitor proliferation. Thus, Breasi-CRISPR can efficiently model MPPH syndrome, and may be a powerful method to add to the toolbox of those investigating the functional impact of patient variants in neurodevelopmental disorders.

ORGANISM(S): Mus musculus

PROVIDER: GSE302315 | GEO | 2025/07/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Breasi-CRISPR Ccnd2 Thr280Ala mutation E13.5-E15.5 embryonic mouse cortex

Project description:Here we demonstrate the ability to model patient variants associated with two different NDDs in vivo using Breasi-CRISPR. We first model periventricular nodular heterotopia (PVNH), a neuronal migration disorder (Heinzen et al., 2018; Walters et al., 2018). We use Breasi-CRISPR to insert two patient analogous protein truncating variants in MAP1B, resulting in a significant defect in migration. We were able to validate that MAP1B fragments are being produced from these protein truncating variants, but the fragments do not act as a dominant negative. Next, we modeled a patient variant in CCND2 (encoding the protein cyclin D2) associated with megalencephaly postaxial polydactyly polymicrogyria hydrocephalus (MPPH) syndrome (Mirzaa et al., 2014). The unifying pathogenic mechanism underlying MPPH syndrome is believed to be excessive cyclin D2, a cell cycle regulator known to promote cell cycle progression. Modeling the repeated variant Thr280Ala caused an increase in the number of cells in S phase, an increase in progenitor numbers, an accumulation of cyclin D2 protein, and a tangential expansion of the cortex. We wondered if Breasi-CRISPR would be efficient enough to notice transcriptomic changes via bulk RNA sequencing of the targeted area. Indeed, we found that introduction of the MPPH syndrome variant caused an upregulation of genes and pathways important in tissue growth and a downregulation of those important in cell differentiation. Taken together we demonstrate that Breasi-CRISPR is efficient enough to model patient analogous variants, mirroring patient phenotypes and enabling investigation of NDDs.

2024-12-08 | GSE249900 | GEO

CRISPR-Mediated Multiplexed Epigenomic Perturbation of Putatively Functional ASoC Sites in Human Neural Progenitor Cell Model at Single-cell Resolution

Project description:Functional interpretation of noncoding disease variants, which likely regulate gene expression, has been challenging. Chromatin accessibility (openness) strongly influences gene expression in neurodevelopment; however, to what extent genetic variants can alter chromatin openness in the context of brain disorders/traits is largely unknown. Using human induced pluripotent stem cell (iPSC)-derived neurons as a neurodevelopmental model, we identified abundant open-chromatin regions absent in brains and thousands of genetic variants exhibiting allele-specific open-chromatin (ASoC). ASoC variants are overrepresented in brain enhancers, transcription-factor-binding sites, and quantitative-trait-loci affecting histone modifications or DNA methylation. ASoC variants are also highly enriched for those associated with brain disorders/traits. Following-up schizophrenia-associated ASoC variants by multiplex epigenomic perturbation, computational fine-mapping, and CRISPR-editing further confirmed their regulatory activities and cis-targeted genes. Our study provides the first snapshot of neuronal ASoC landscape and a framework for prioritizing functional disease variants.

2020-05-05 | GSE132757 | GEO

Array-CGH in a boy with an occurrence of neurodevelopmental disorders and epilepsy

Project description:This analysis includes the whole-genome screening of unbalanced chromosomal rearrangements (copy-number variants; CNV) in a boy with neurodevelopmental disorders and epilepsy.

2020-01-31 | E-MTAB-8147 | biostudies-arrayexpress

Protein Profiling of human iPSC-derived cardiomyocytes with a recessive LZTR1 variant in comparison to CRISPR/Cas9-corrected cells

Project description:Genetic variants in LZTR1 are associated with the development of Noonan syndrome. Here, we analyzed the proteome of cultured cardiomyocytes derived from hiPSCs with a pathological homozygous LZTR1 variant L580P in comparison to heterozygous and homozygous CRISPR/Cas9-corrected iPSC lines.

2024-07-02 | PXD038417 | Pride

Functional genomic consequences of MBD5 knockdown in mouse brain and CRISPR-derived neurons [mouse]

Project description:Background: MBD5, encoding the methyl-CpG-binding domain 5 protein, has been proposed as a necessary and sufficient driver of the 2q23.1 microdeletion syndrome. De novo missense and protein-truncating variants from exome sequencing studies have directly implicated MBD5 in the etiology of autism spectrum disorder (ASD) and related neurodevelopmental disorders (NDDs). However, little is known concerning the specific function(s) of MBD5. Methods: In an effort to gain insight into the complex interactions associated with genetic alteration of MBD5 in individuals with ASD and related NDDs, we explored the transcriptional landscape of MBD5 haploinsufficiency across multiple mouse brain regions of the heterozygous hypomorphic Mbd5+/GT mouse model and compared these results to CRISPR-mediated mutations of MBD5 in human iPSC-derived neuronal models. Results: Gene expression analyses of three brain regions from Mbd5+/GT mice showed cortex as the region most affected by the knockdown, indicating context-dependent effects. Gene co-expression network analyses revealed gene clusters that are associated with MBD5 knockdown and enriched for GPCR signaling and terms related to ciliary function. We also identified genes that were downregulated in both models such as EPHA3, OLIG1, related to neuronal development and glial function. Limitations: These analyses were performed in a limited number of brain regions and neuronal models, and the effects of the gene knockdown are subtle. As such, these results will not reflect the full extent of MBD5 disruption across brain tissues during early brain developmentneurodevelopment in ASD. Conclusions: Our study points to transcriptional consequences of Mbd5 disruption in the brain and suggests a link between MBD5 and pathways such as ciliary function that are associated with established developmental disorders and syndromes.

2020-01-28 | GSE144277 | GEO

Targeted next-generation sequencing in family with an occurrence of neurodevelopmental disorders and epilepsy

Project description:We performed a targeted NGS using the commercial gene panel design ClearSeq Inherited Disease (Agilent Technologies) to identify the pathogenic sequence variants in two boys with neurodevelopmental disorders and epilepsy and their unaffected parents

2019-12-31 | E-MTAB-8131 | biostudies-arrayexpress

Functional genomic consequences of MBD5 knockdown in mouse brain and CRISPR-derived neurons [cell lines]

2020-01-28 | GSE144279 | GEO

Target-agnostic discovery of Rett Syndrome therapeutics by coupling computational network analysis and CRISPR-enabled in vivo disease modeling

Project description:It is difficult to develop effective treatments for neurodevelopmental genetic disorders, such as Rett syndrome, which are caused by a single gene mutation but trigger changes in numerous other genes, and thereby also severely impair functions of organs beyond the central nervous system (CNS). This challenge is further complicated by the lack of sufficiently broad and biologically relevant drug screens, and the inherent complexity in identifying clinically relevant targets responsible for diverse phenotypes. Here, we combined human gene regulatory network-based computational drug prediction with in vivo screening in a population-level diversity, CRISPR-edited, Xenopus laevis tadpole model of Rett syndrome to carry out target-agnostic drug discovery, which rapidly led to the identification of the FDA-approved drug vorinostat as a potential repurposing candidate. Vorinostat broadly improved both CNS and non-CNS (e.g., gastrointestinal, respiratory, inflammatory) abnormalities in a pre-clinical mouse model of Rett syndrome. This is the first Rett syndrome treatment to demonstrate pre-clinical efficacy across multiple organ systems when dosed after the onset of symptoms, and network analysis revealed a putative therapeutic mechanism for its cross-organ normalizing effects based on its impact on acetylation metabolism and post-translational modifications of microtubules.

2022-03-22 | GSE199049 | GEO

Mitochondrial Proteostasis Requires Genes Encoded in a Neurodevelopmental Syndrome Locus

Project description:Eukaryotic cells maintain proteostasis through mechanisms that require cytoplasmic and mitochondrial translation. Genetic defects affecting cytoplasmic translation perturb synapse development, neurotransmission, and are causative of neurodevelopmental disorders such as Fragile X syndrome. In contrast, there is little indication that mitochondrial proteostasis, either in the form of mitochondrial protein translation and/or degradation, is required for synapse development and function. Here we focus on two genes deleted in a recurrent copy number variation causing neurodevelopmental disorders, the 22q11.2 microdeletion syndrome. We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis. Our Drosophila studies show that mitochondrial ribosome function is necessary for synapse neurodevelopment, function, and behavior. We propose that mitochondrial proteostasis perturbations, either by genetic or environmental factors, are a pathogenic mechanism for neurodevelopmental disorders.

2022-02-17 | PXD025289 | Pride

Project description:Familial SYN1 pathogenic variants related Neurodevelopmental Disorders in Asian Pediatric Patients

| PRJNA726857 | ENA